Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor
In Vivo · 2024
DOI: 10.21873/invivo.13415 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Tomonobu Yamada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Atherosclerosis, Hyperlipidemias. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Atherosclerosis is known as a major risk factor for cardiovascular disease, and development of an animal model of atherosclerosis is required to investigate its clinical pathogenesis. We studied the optimal amount of cholesterol in the diet and the optimal experimental period for development of a Microminipig model of atherosclerosis for the evaluation of a hydroxymethylglutaryl-CoA reductase (HMGCR) inhibitor (atorvastatin). MATERIALS AND METHODS: Eighteen male animals (3-4 months old) were divided into 3 groups. Group 1 consisted of control animals receiving a normal chow diet, Group 2 animals received a high fat (12% w/w) and low cholesterol (0.1% w/w) diet (HFLCD), and Group 3 animals received HFLCD+statin for 12 weeks. Animals received statin at 3 mg/kg body weight per day. HFLCD did not down-regulate the hepatic expression of HMGCR mRNA. RESULTS: HFLCD increased body, omentum, and mesenteric adipose tissue weight, and induced hypercholesterolemia and atherosclerotic lesions in the abdominal aorta. HFLCD+statin inhibited hypercholesterolemia and atherosclerotic lesions, but not obesity. CONCLUSION: A microminipig atherosclerosis model induced by HFLCD can be used in the evaluation of HMGCR inhibitors for the treatment of hypercholesterolemia and atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
- Shin Nippon Biomedical Laboratories, Ltd., Kagoshima, Japan.
- Laboratory of Veterinary Pathology, School of Veterinary Medicine, Kitasato University, Aomori, Japan; hirok@vmas.kitasato-u.ac.jp.
- Laboratory of Veterinary Histopathology, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.
- Veterinary Teaching Hospital, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.
- Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; akit09@m3.kufm.kagoshima-u.ac.jp.
Zitieren
APA
Yamada, T., Kawaguchi, H., Matsuoka, A., Akioka, K., Miura, N., Izumi, H., & Tanimoto, A. (2024). Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor. In Vivo. https://doi.org/10.21873/invivo.13415
Vancouver
Yamada T, Kawaguchi H, Matsuoka A, Akioka K, Miura N, Izumi H, et al. Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor. In Vivo. 2024. doi:10.21873/invivo.13415
BibTeX
@article{Yamada2024,
author = {Yamada, Tomonobu and Kawaguchi, Hiroaki and Matsuoka, Aki and Akioka, Kohei and Miura, Naoki and Izumi, Hiroyuki and Tanimoto, Akihide},
title = {Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13415}
}
EUVIMED